Valley National's Q3 profit jumps 55.6% on higher net interest income and lower provisions, lifting its stock by 4.2%.

HWM's defense aerospace strength, fueled by F-35 engine parts demand and new contracts, is propelling robust revenue growth.

Service Corporation looks well-positioned ahead of Q3 results, driven by steady demand, expanding funeral services and a balanced capital strategy.

Tech stocks are expected to deliver very strong earnings reports for the third quarter led by Big Tech stalwarts Microsoft Corp (NASDAQ:MSFT), Alphabet Inc (NASDAQ:GOOG) and Amazon.com Inc (NASDAQ:AMZN) on robust AI enterprise demand, analysts at Wedbush believe. Wedbush noted that field checks suggest cloud businesses at these companies experienced significant uptake of AI solutions, contributing to expectations for solid revenue and profit growth.

KO's Q3 showed North America leading with stronger volumes and value share gains, even as global markets face uneven momentum and macro headwinds.

FTI posts a strong Q3 earnings beat as Subsea growth lifts profits, cash flow surges and a $2B share buyback is unveiled.

VRSK is set to post third-quarter fiscal 2025 results on Oct. 29, with expectations of solid revenue growth and margin gains from cost control.

Yesterday, Target Corporation announced news that no one wants to hear—especially just before the holidays.

UnitedHealth Group Incorporated and Centene Corporation remain heavily discounted after recent selloffs, but are poised for recovery ahead of Q3 earnings. Both UNH and CNC withdrew guidance in 2025 due to rising healthcare utilization and margin pressure, but recent signals suggest stabilization and improving outlooks. CMS's commitment to higher Medicare Advantage rates in 2026 and improving Medicaid margins supports a bullish stance on both stocks.

NGD's Q3 earnings could shine on surging gold and copper prices, stronger output and lower costs as it readies results on Oct. 28.

CLB beats Q3 earnings estimates on strong Production Enhancement results. However, earnings dip y/y due to the Reservoir Description segment's weakness.

CDE Q3 results are expected to shine, fueled by stronger gold and silver output and higher prices.

Kinross Gold is rated a "Buy," supported by strong free cash flow, low P/E, and robust operational performance. Q2 results featured a major earnings and revenue beat, lower unit costs, and significant share buybacks, boosting balance sheet strength. Kinross Gold's earnings outlook is bright, with EPS seen surpassing $2 by FY 2026 and strong analyst upgrades, though cyclical risks remain.

Shares of Advanced Micro Devices jumped on a report that IBM can utilize the company's chips to run certain quantum computing algorithms. IBM plans to launch a quantum computer by 2029 and announced a partnership with AMD in August.

Gold endured a volatile week, rallying early before breaking sharply lower toward the $4,000 support zone. Rising volume suggests a potential top forming, with a corrective pullback toward $3,800 seen as a healthy normalization after recent parabolic gains.

PRU's third-quarter results are likely to reflect higher net investment spread, favorable underwriting results, and positive net flows.

Intel (INTC) shares rose Friday morning after the chipmaker swung to a profit that sailed past Wall Street expectations, signaling its closely watched turnaround plan is gaining traction.

Shares of Alaska Air Group (ALK) flew lower Friday after the airline turned in quarterly profits that were less than expected and reported an IT outage that forced a system-wide ground stop of all flights of its namesake carrier and Horizon Air.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Upstart, Inc. (NASDAQ: UPST) breached their fiduciary duties to shareholders. If you currently own Upstart stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal ri.

PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced updated data from the Phase 2 pivotal portion of the ongoing PYNNACLE clinical trial. Results were presented today in an oral presentation by Alison M. Schram, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center and PYNNACLE Study Investigator, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts. The ongoing Phase 1/2 PYNNACLE clinical trial is …